GlassScriptPhysician profile
Gina S Rushing
NPI 1922056845
$5,015.19
in general payments reported to CMS, 2019-2025
44 companies · $316 in 2025
The $316 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,131 · 2020: $706 · 2021: $948 · 2022: $716 · 2023: $590 · 2024: $608 · 2025: $316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,514.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,513.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $507.00 | 2019-2022 | |
| Novo Nordisk INC | $503.62 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $466.42 | 2019-2023 | |
| Abbvie INC. | $409.50 | 2020-2025 | Vraylar, Linzess, Viberzi |
| Amgen INC. | $313.85 | 2019-2023 | Prolia, Evenity, Otezla |
| Otsuka America Pharmaceutical, INC. | $296.33 | 2021-2025 | Rexulti |
| Amarin Pharma, INC. | $287.28 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $261.81 | 2019-2025 | Breztri, Airsupra |
| Lilly USA, LLC | $247.49 | 2020-2024 | Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $202.51 | 2019-2025 | |
| Astellas Pharma US INC | $148.20 | 2019-2024 | Veozah |
| Sunovion Pharmaceuticals INC. | $129.55 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $118.28 | 2019-2020 | |
| Glaxosmithkline, LLC. | $108.46 | 2019-2022 | |
| Ucb, INC. | $97.38 | 2022-2024 | Nayzilam, Briviact |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gina Rushing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.